治疗早期未分化关节炎:直接与间接试验证据的系统评价与Meta分析
该系统评价与Meta分析检索4个电子数据库至2016年1月,纳入9项研究,评估甲氨蝶呤、阿巴西普、英夫利西单抗、关节腔或肌注糖皮质激素及放射性滑膜切除术对未分化关节炎(UA)的疗效。治疗组12个月时进展为类风湿关节炎(RA)的比率低于安慰剂或无治疗组(OR 0.49,95%CI 0.26-0.90),甲氨蝶呤直接比较显示12个月进展风险降低(OR 0.13,95%CI 0.03-0.48),但30或60个月时差异不再显著。间接比较中甲氨蝶呤(OR 0.16,95%CI 0.08-0.33)和肌注甲泼尼龙(OR 0.72,95%CI 0.53-0.99)12个月进展风险显著降低。
要点
- 治疗UA可显著降低12个月进展为RA的风险(OR 0.49,95%CI 0.26-0.90)。
- 甲氨蝶呤直接比较12个月进展风险降低(OR 0.13,95%CI 0.03-0.48),但30或60个月时差异不再显著。
- 间接比较中甲氨蝶呤和肌注甲泼尼龙12个月进展风险显著降低。
核心结论
- 治疗UA患者可显著延迟RA的发展,其中甲氨蝶呤效果最大,提示存在早期治疗UA以延缓进展为RA的机会窗口。
研究设计与样本
- 系统评价与Meta分析,检索4个电子数据库(从建库至2016年1月)、clinicaltrials.gov及相关文献书目,由两名评价员独立筛选和评估研究,最终纳入9项研究。
主要发现
- 治疗组12个月时进展为RA的比率低于安慰剂或无治疗组(OR 0.49,95%CI 0.26-0.90)。
- 直接Meta分析中,甲氨蝶呤治疗患者12个月时进展为RA的风险低于未用甲氨蝶呤患者(OR 0.13,95%CI 0.03-0.48),但30或60个月时差异不再显著。
- 间接比较中,大多数干预措施12个月时进展为RA的风险低于安慰剂,甲氨蝶呤(OR 0.16,95%CI 0.08-0.33)和肌注甲泼尼龙(OR 0.72,95%CI 0.53-0.99)达到统计学显著性。
- 大多数单个干预措施纳入的研究数量有限。
临床怎么用
- 对于UA患者,可考虑早期使用甲氨蝶呤等治疗以延迟进展为RA,但长期获益(30或60个月)未证实,需个体化评估。
局限性
- 大多数单个干预措施纳入的研究数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We undertook a systematic review and meta-analysis of direct and indirect trial evidence to evaluate the efficacy of treatments for patients with undifferentiated arthritis (UA). METHODS: We searched 4 electronic databases from inception to January 2016, clinicaltrials.gov, and bibliographies of relevant articles. Two reviewers independently screened and evaluated the studies. The primary outcome was development of rheumatoid arthritis (RA). RESULTS: Nine studies were included. Interventions included methotrexate, abatacept, infliximab, intraarticular or intramuscular glucocorticoids, and radiation synovectomy. Treating patients resulted in lower rates of RA at 12 months compared to placebo or no treatment (odds ratio [OR] 0.49 [95% confidence interval (95% CI) 0.26, 0.90]). From direct meta-analysis, patients treated with methotrexate were less likely to develop RA at 12 months compared to patients treated without methotrexate (OR 0.13 [95% CI 0.03, 0.48]). This difference was no longer significant at 30 or 60 months. From indirect comparisons, most interventions showed decreased risk of developing RA compared to placebo at 12 months, reaching statistical significance for methotrexate (OR 0.16 [95% CI 0.08, 0.33]) and intramuscular methylprednisolone (OR 0.72 [95% CI 0.53, 0.99]). Most individual interventions included a limited number of studies. CONCLUSION: Treating patients with UA resulted in a statistically significant delay in the development of RA, with the largest effect observed for methotrexate. These findings suggest that there is a window of opportunity to treat patients with UA early, to delay subsequent progression to RA.
引用
- Lopez-Olivo MA, Kakpovbia-Eshareturi V, des Bordes JK, et al. Treating Early Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Direct and Indirect Trial Evidence. Arthritis Care Res (Hoboken). 2018. PMID: 29161466. doi:10.1002/acr.23474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。